Form 4: Vaxcyte Executive Granted Performance-Based Stock Options and Restricted Stock Units

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., received performance-based stock options and restricted stock units on November 7, 2024, as part of a company-wide grant.

Summary

• On November 7, 2024, Andrew Guggenhime, the President and CFO of Vaxcyte, Inc., was granted performance stock options to purchase 87,481 shares of the company's common stock at an exercise price of $102.70 per share.
• These options vest in thirds on the third, fourth, and fifth anniversaries of the grant date, subject to a service-based condition.
• A performance-vesting condition also requires the trading price of Vaxcyte's common stock to average at least $154.05 (150% of the grant date closing price) over a one-year period.
• Guggenhime also received performance restricted stock units (PSUs) representing the contingent right to receive 35,661 shares of Vaxcyte's common stock.
• The number of shares deliverable for the PSUs can range from 0% to 250% of the target number, depending on Vaxcyte's total shareholder return (TSR) percentile rank within a peer group over a four-year performance period starting November 7, 2024.
• Continuous service with Vaxcyte through the performance period is also required for the PSUs to vest.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future performance. The performance-based conditions suggest a positive outlook, but the actual value of the grants depends on future performance.

Positives

• The performance-based nature of the stock options and PSUs aligns executive compensation with the company's long-term performance and shareholder value.
• The vesting conditions encourage continued service and incentivize executives to drive stock price appreciation.

Risks

• The performance-vesting condition for the stock options may not be met if Vaxcyte's stock price does not reach and sustain the $154.05 target.
• The actual number of shares received from the PSUs could be significantly lower than the target if Vaxcyte's TSR performance is poor relative to its peer group.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules and performance conditions of the granted securities.

Industry Context

This type of equity grant is common in the biotechnology industry to incentivize executives and align their interests with those of shareholders, particularly in companies with long development timelines and significant regulatory hurdles.

Comparison to Industry Standards

• Performance-based equity compensation is a standard practice among publicly traded biotech companies.
• Companies like Moderna, BioNTech, and Novavax also utilize stock options and restricted stock units with vesting schedules tied to performance metrics and continued service.
• The specific performance metrics and vesting terms vary depending on the company's stage of development, strategic goals, and compensation philosophy.
• The TSR-based performance condition for the PSUs is a common approach to align executive compensation with shareholder returns, similar to practices at other companies in the pharmaceutical and biotechnology sectors.

Stakeholder Impact

• Shareholders: The performance-based compensation structure aims to align executive interests with shareholder value creation.
• Employees: The company-wide grant suggests a broader effort to incentivize and retain employees.
• Executives: The grants provide significant potential upside for executives if the company performs well.

Key Dates